

A New G-Quadruplex with Hairpin Loop Immediately Upstream of the Human BCL2 P1 Promoter Modulates Transcription


Buket Onel,[†] Megan Carver,[‡] Guanhui Wu,[‡] Daria Timonina,[†] Salil Kalarn,[†] Marti Larriva,[‡] and Danzhou Yang^{*,‡,§,||,†}

[‡]Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, 1703 E. Mabel St, Tucson, Arizona 85721, United States

[†]Department of Chemistry and Biochemistry, [§]BIO5 Institute, ^{||}The Arizona Cancer Center, University of Arizona, Tucson, Arizona 85719, United States

S Supporting Information

ABSTRACT: The abnormal overexpression of the BCL2 gene is associated with many human tumors. We found a new 28-mer G-quadruplex-forming sequence, P1G4, immediately upstream of the human BCL2 gene P1 promoter. The P1G4 is shown to be a transcription repressor using a promoter-driven luciferase assay; its inhibitory effect can be markedly enhanced by the G-quadruplex-interactive compound TMPyP4. G-quadruplex can readily form in the P1G4 sequence under physiological salt condition as shown by DMS footprinting. P1G4 and previously identified Pu39 G-quadruplexes appear to form independently in adjacent regions in the BCL2 P1 promoter. In the extended BCL2 P1 promoter region containing both Pu39 and P1G4, P1G4 appears to play a more dominant role in repressing the transcriptional activity. Using NMR spectroscopy, the P1G4 G-quadruplex appears to be a novel dynamic equilibrium of two parallel structures, one regular with two 1-nt loops and a 12-nt middle loop and another broken-strand with three 1-nt loops and a 11-nt middle loop; both structures adopt a novel hairpin (stem–loop duplex) conformation in the long loop. The dynamic equilibrium of two closely related structures and the unique hairpin loop conformation are specific to the P1G4 sequence and distinguish the P1G4 quadruplex from other parallel structures. The presence of P1G4 and Pu39 in adjacent regions of the BCL2 P1 promoter suggests a mechanism for precise regulation of BCL2 gene transcription. The unique P1G4 G-quadruplex may provide a specific target for small molecules to modulate BCL2 gene transcription.



■ INTRODUCTION

The B-cell lymphoma-2 (BCL2) protein belongs to the BCL2 family of proteins and plays an essential role in the regulation of programmed cell death, or apoptosis.^{1,2} The abnormal overexpression of the BCL2 protein is linked to a large number of cancers.^{3–7} Moreover, elevated levels of BCL2 are found to promote resistance to chemotherapy and γ radiation.^{8,9} Therefore, BCL2 is considered to be an attractive target for cancer therapeutics. The most intensively pursued strategy is inhibiting BCL2 interactions with BH3-only proteins by small molecules;^{10,11} a BCL2-selective inhibitor, ABT-199, was recently developed to avoid thrombocytopenia caused by bcl-X_L inhibition and in Phase III clinical trials.¹² However, the dynamic nature of protein–protein interactions and acquired resistance present challenges for BCL2 inhibitors.^{13–15} Modulation of BCL2 at the transcriptional level presents a compelling strategy for cancer therapeutics.

The major P1 promoter of the human BCL2 gene is located in the untranslated first exon, 1386 to 1432 base pairs upstream of the translation start site.^{3,16} It is a TATA-less, GC-rich promoter with multiple transcription start sites (–1394, –1399,

–1406, –1410, and –1432) and is positioned in proximity to a nuclease hypersensitive site^{16,17} (Figure 1A). We have previously identified a 39-base-pair GC-rich region located 1489 to 1451 base pairs upstream of the translation start site (Figure 1A), whose G-rich strand (Pu39) can form two interchangeable G-quadruplex (G4) structures, a hybrid-type G-quadruplex^{18,19} and a parallel G-quadruplex with a 13-nt middle loop.²⁰ Stabilization of the BCL2 G-quadruplex by quindoline derivatives was reported to decrease mRNA and protein levels of BCL2 and lead to apoptosis in HL-60 cells.²¹ Also reported is a G-rich sequence located 176 bp upstream of the P1 promoter which can form a stable G-quadruplex structure in the presence of peptide nucleic acid (PNA) molecules.²²

However, in our functional study of the BCL2 P1 promoter activity using a luciferase reporter system in tumor cells, we found that the construct with a complete G-quadruplex-knockout Pu39 mutant was still affected by G4-interactive

Received: August 19, 2015

Published: February 3, 2016




Figure 1. (A) Promoter structure of the human *BCL2* gene. Shown in the inset is the P1G4 sequence with guanine runs of the purine-rich strand underlined. Transcriptional start sites of the P1 promoter are indicated using arrows. (B) P1G4-WT and P1G4KO constructs, as well as Dual-WT (containing both Pu39 and P1G4), Dual-Pu39KO (Pu39 G-quadruplex knockout), Dual-P1G4KO (P1G4 G-quadruplex knockout), and Dual-KOKO (double knockout) used for promoter-driven luciferase assay. P1G4 and Pu39 sequences are enclosed by blue and red boxes, respectively. G-runs are underlined; the mutations in the G-quadruplex knockout constructs are shown in red. (C) Luciferase activity of P1G4-WT and P1G4KO constructs in the absence and presence of TMPyP4 and TMPyP2 at 5 μ M in MCF-7 cells. Each data point is the average of three independent experiments. (D) Luciferase activity of Dual-WT, Dual-Pu39KO, Dual-P1G4KO, and Dual-KOKO constructs in the absence and presence of 5 μ M TMPyP4 and TMPyP2 in MCF-7 cells. Each data point is the average of three independent experiments. (E) Structures of TMPyP4 and TMPyP2. (F) Structure of G-tetrad.

compounds. Careful examination of the *BCL2* P1 promoter sequence revealed a 28-bp GC-rich region immediately upstream of the *BCL2* P1 promoter (−1439 to −1412 bp) (P1G4, Figure 1A). Previous studies have shown that deletion

of this promoter region increased the promoter activity more than 2-fold.²³ Several transcription factors have been reported or suggested to bind to this region, such as SP1 and AP2.¹⁶ Herein we reported that a stable G-quadruplex can readily form in the P1G4 sequence under physiological salt condition and that the new P1G4 functions as a transcription repressor. The P1G4 G-quadruplex appears to be a dynamic equilibrium of two parallel structures, one regular with two 1-nt loops and a 12-nt middle loop and another broken-strand with three 1-nt loops and a 11-nt middle loop; both structures adopt a novel hairpin (stem–loop duplex) structure in the long loop. The unique P1G4 G-quadruplex with a hairpin loop may provide a specific recognition site for small molecules. P1G4 and previously identified Pu39 G-quadruplexes appear to form independently in adjacent regions. In the extended *BCL2* P1 promoter region containing both Pu39 and P1G4, P1G4 appears to play a more dominant role in repressing the transcriptional activity. The novel P1G4 quadruplex in the 28-bp GC-rich element immediately upstream of the *BCL2* P1 promoter that acts as a transcriptional repressor adds to our understanding of *BCL2* transcriptional control, and to the diversity of parallel G-quadruplexes.

RESULTS

BCL2 P1G4 Functions As a Transcriptional Repressor.

To determine the biological function of P1G4, a P1G4WT construct was created by inserting the (−1390 to −1444 bp) human *BCL2* P1 promoter sequence in a promoter-less pGL4.13 vector upstream of the firefly luciferase reporter gene (Figure 1B). The SV40 promoter in pGL4.13 was deleted, as it was found to contain a GC-rich region that can be affected by G-quadruplex-interactive compounds. The Pu39 region was intentionally excluded to isolate the biological effect of P1G4 on gene transcription. We also generated a control construct with a mutated P1G4KO sequence that was not able to form G-quadruplex (Figure 1B). MCF-7 cells were used because they express high levels of *BCL2*.²⁴ Our results showed that the luciferase activity of the construct containing the P1G4KO sequence is more than 2.5-fold greater than that with the wild-type *BCL2* P1G4 promoter sequence (Figure 1C left), indicating that the P1G4 functions as a transcriptional repressor.

We then carried out luciferase assays using P1G4WT and P1G4KO constructs in the presence of 5 μ M TMPyP4, a G-quadruplex-interactive compound, and its positional isomer, TMPyP2, a poor G-quadruplex-interactive compound (Figure 1E). In the P1G4WT construct, TMPyP4 showed a pronounced inhibitory effect on the promoter activity, whereas TMPyP2 showed a much weaker inhibition (Figure 1C middle, Supplemental Table S1). In contrast, in the P1G4KO construct, TMPyP4 showed a much-reduced inhibitory effect on the promoter activity (Figure 1C right, Supplemental Table S1). These results indicated that the inhibitory effect of P1G4, but not P1G4KO, can be markedly enhanced by the G-quadruplex-interactive compound TMPyP4.

To examine the function of both P1G4 and Pu39 in the *BCL2* P1 promoter, we further generated a construct with an extended human *BCL2* P1 promoter sequence that contains both Pu39 and P1G4 regions in the pGL4.13 vector (Dual-WT, Figure 1B). We then generated knockout constructs with the Pu39KO sequence that was not able to form Pu39 G-quadruplex, or the P1G4KO sequence that was not able to form P1G4 G-quadruplex, or a double-knockout sequence that

was not able to form either P1G4 or Pu39 G-quadruplex, respectively (Dual-Pu39KO, Dual-P1G4KO, Dual-KOKO, Figure 1B). The luciferase assays in MCF-7 cells showed that the luciferase activity of the construct containing the P1G4KO sequence (Dual-P1G4KO) is again more than 2-fold greater than that with the wild-type BCL2 promoter sequence Dual-WT (Figure 1D left), in agreement with the previous data that the P1G4 functions as a transcriptional repressor. Interestingly, the luciferase activity of the construct containing the Pu39KO sequence is about 50% of that with the wild-type BCL2 promoter sequence (Figure 1D left), suggesting that Pu39 may function as a transcriptional activator. When both Pu39 and P1G4 quadruplexes were knocked out (Dual-KOKO, Figure 1B), the luciferase activity was more than 1.5-fold greater than that with the wild-type BCL2 promoter sequence Dual-WT (Figure 1D left), indicating that P1G4 plays a more dominant role in repressing the transcriptional activity. The luciferase assays in the presence of TMPyP4 and TMPyP2 showed that TMPyP4 induced a clear inhibitory effect on the promoter activity, whereas TMPyP2 did not appear to affect the promoter activity (Figure 1D right, Supplemental Table S1), indicating that the G-quadruplex-interactive compound TMPyP4 can markedly enhance the inhibitory effect of P1G4 on gene transcription. As TMPyP4 is known to be a nonselective G-quadruplex-interactive compound, it can stabilize both the Pu39 and P1G4 quadruplexes. The inhibitory effect of TMPyP4 was shown to be more pronounced in the Pu39KO construct where P1G4 is intact (Figure 1D right, Supplemental Table S1), again suggesting that P1G4 quadruplex plays a more dominant role in repressing the transcriptional activity in the BCL2 P1 promoter.

P1G4 Forms a Stable G-Quadruplex under Physiologically Relevant Ionic Conditions. To confirm that the P1G4 forms a stable G-quadruplex under physiologically relevant ionic conditions, we carried out dimethyl sulfate (DMS) footprinting experiments. The guanine N7 in a G-tetrad is involved in Hoogsten hydrogen bonding (Figure 1E) and is protected from DMS methylation and piperidine cleavage, in contrast to the guanines in single- or double-stranded DNA.¹⁹ Hence, DMS footprinting provides a useful tool to determine the tetrad guanines of a G-quadruplex. The P1G4 sequence consists of five runs of three consecutive guanines (Figure 2A). The results of DMS footprinting analysis on the wild-type P1G4 in the absence and presence of 140 mM K⁺ at pH 7 are shown in Figure 2B left. G-runs I, II, IV and V, each consisting of three consecutive guanines, appeared to be protected from DMS methylation. G8 appeared to be less protected from cleavage compared to other guanines in G-run II. G10, G12, G14, and G15 showed complete cleavage, indicating that these guanines are not involved in G-tetrad formation. G-run III appeared to be cleaved; the mutant P1G4 RunIII-G/T sequence (Figure 2A), in which all guanines in G-run III were mutated to thymine, showed a similar DMS footprinting cleavage pattern to that of the wild-type BCL2 P1G4 in the presence of 140 mM K⁺, but with G8 more protected in the mutant sequence (Figure 2B). As a control, we performed DMS footprinting on a complete knockout mutant sequence P1G4-KO (Figure 2A), in which the middle guanine of each G-run was mutated to a thymine residue. The result showed complete cleavage at each guanine position, both in the absence and presence of K⁺ (Figure 2B), indicating G-quadruplex was not able to form in the P1G4-KO sequence.




Figure 2. (A) The promoter sequence of the BCL2 P1G4 and its modifications. The top sequence is the 29-mer wild-type G-rich sequence (P1G4). The five G-runs are underlined and numbered. P1G4 RunIII-G/T and P1G4 KO are modified P1G4 sequences with G to T mutations shown in red. P1G4T is P1G4 sequence with a flanking T at both ends. (B) DMS footprinting of P1G4, P1G4 RunIII-G/T, P1G4 KO, and P1G4T.

The disruption of the P1G4 quadruplex in P1G4-KO was also supported by CD data (Figure S1).

We also performed DMS footprinting on a 94-nt extended BCL2 promoter sequence that contains both Pu39 and P1G4, in the absence and presence of 140 mM K⁺ at pH 7 (Figure 3). Even in the presence of Pu39, G-quadruplexes were clearly formed in the P1G4 segment (Figure 3 left). The DMS protection pattern is similar to that observed for the P1G4 itself, but with more protection on G-run III in the extended 94-nt sequence. On the other hand, the DMS cleavage pattern of the Pu39 segment (Figure 3 right) is also similar to what was previously observed for Pu39 itself.²⁰ Therefore, Pu39 and P1G4 G-quadruplexes appeared to form independently in the extended BCL2 promoter sequence.

The P1G4 G-Quadruplex Is a Dynamic Equilibrium of Two Parallel Structures, Both Containing a Stem–Loop Hairpin in the Middle Loop. To determine the folding structure of the major G-quadruplex formed in the BCL2 P1G4 sequence, we performed NMR studies in combination with CD and EMSA. The P1G4 with five runs of three consecutive guanines (Figure 4A) can form multiple G-quadruplexes. 1D ¹H NMR spectrum of P1G4 in 50 mM K⁺ solution showed sharp peaks at 10.5–12 ppm, characteristic of imino protons of tetrad guanines (Figure 4B top). However, higher order structures appeared to form in P1G4 as indicated by elevated baselines.

The tendency for the formation of higher-order G-quadruplexes has been observed in other G-rich quadruplex-forming sequences.^{20,25} The P1G4T sequence (Figure 4A), with thymine at both ends, gave rise to improved NMR spectral quality with decreased higher-order structures (Figure 4B middle). This was confirmed by EMSA experiments: P1G4




Figure 5. Imino H1 proton assignments of P1G4T by 1D ^{15}N -filtered experiments using site-specifically labeled oligonucleotides at 25 °C, in 25 mM K^+ , pH 7.0.




Figure 6. Schematic drawing of two parallel-stranded P1G4 G-quadruplexes in dynamic equilibrium (G = red, A = green, C = yellow, T = blue).

we were able to detect several guanine imino protons in ^{15}N -G-labeled P1G4 (Figure S4), which were shown to be at the same positions as those in P1G4T, suggesting the same major G-quadruplex conformation.

Surprisingly, G19 of G-run III showed a clear imino proton peak at ~ 11 ppm (Figure 5), indicating the potential involvement of G19 in a tetrad formation. On the other hand, of the three guanines on G-run II, the imino proton peak of G8 appeared to be weaker than those of G6 and G7 (Figure 5), suggestive of a more dynamic conformation of G8. The dynamic nature of G8 was also shown in the DMS footprinting data, in that G8 is less protected from DMS cleavage than the other two guanines on G-run II (Figure 2B). Upon the G-to-T mutation of run-III including G19, the partial cleavage of G8 disappeared, indicating complete involvement of G8 in tetrad formation (Figure 2B). It thus appeared that a second G-quadruplex structure forms in P1G4T, where G8 of the bottom tetrad is substituted by G19 resulting in a parallel structure containing a broken strand, with three 1-nt loops and one 11-nt loop (P1G4B, Figure 6 right). Indeed, P1G4T with G8-to-T mutation (P1G4T_{G8T}) shows a ^1H NMR spectrum similar to that of P1G4T (Figure 4B bottom), and a very similar CD spectrum (Figure S5), indicative of a similar major G-quadruplex formation. The two parallel G-quadruplexes differed only in the bottom G-tetrad and appeared to be in dynamic equilibrium (Figure 6), which may provide stability to the major P1G4T G-quadruplex. The same Watson–Crick imino peaks around 13 ppm were observed in P1G4T_{G8T}, indicating the stem loop conformation also formed in the P1G4B structure with a broken strand (Figure 6 right). While G18 did not show an imino proton detectable in the 10.5–12 ppm region, G17 of G-run III showed a weak peak around 10.5 ppm, suggesting that G17 may be involved in a hydrogen-bonded capping structure below the 3' G-tetrad. Depending on the hydrogen-bonding conformation, the imino proton of a guanine residue involved in a capping structure can have a chemical shift around 10.5 ppm, as shown in the major G-quadruplex formed in the VEGF promoter.²⁹ The NMR variable temperature study showed that, while the P1G4 core quadruplex melting temperature was about 65 °C, the melting temperature was around 45 °C for the stem–loop structure of P1G4, and below 35 °C for G17 and thus the 3' capping structure (Figure 4D). With only two detectable Watson–Crick base pairs in the stem–loop hairpin structure of P1G4, a melting temperature of 45 °C is quite remarkable.

It has been recently reported that a pregnanol derivative, NSC 59276 (IMC-76), can bind to the flexible hairpin to shift the dynamic equilibrium between the alternative hairpin and the i-motif formed in the BCL2 P1 promoter.³⁰ We are interested in finding out whether NSC 59276 has an effect on the P1G4 quadruplex-induced transcriptional repression. We first tested the binding of NSC 59276 with the P1G4 quadruplex by NMR. NSC 59276 did not appear to specifically stabilize the hairpin loop within the P1G4 structure (Figure S6A). It did not appear to stabilize the P1G4 quadruplex either, as shown by CD melting of P1G4T in the presence of 4 equiv of NSC 59276, whose T_m is similar to that of free P1G4T DNA. We then examined the effect of NSC 59276 on the luciferase activities of P1G4-WT and P1G4KO constructs. Consistently, NSC 59276 did not show a clear inhibitory effect on the promoter activity in either construct (Figure S6B).

DISCUSSION

It is significant that a stable G-quadruplex is found to form in the P1G4 sequence immediately upstream of the P1 promoter and act as a transcriptional repressor. P1G4 is only 13 nt away from the previously identified Pu39 region, with both regions capable of forming independent G-quadruplexes in the BCL2 P1 promoter sequence. The presence of stable G-quadruplexes in adjacent regions could be important for the precise regulation of BCL2 gene transcription. The major P1 promoter contains multiple transcription start sites (−1394, −1399, −1406, −1410, and −1432); depending on which transcription start site is used, different G4 may be formed. For example, transcription from all start sites except for −1432 allows formation of P1G4 quadruplex, but transcription from the start site −1432 can only permit Pu39 G-quadruplex formation (Figure 1A). In addition, as the transcription-associated negative superhelicity is the driving force for the G-quadruplex formation in proximal promoter regions, the formation of P1G4 and Pu39 G-quadruplexes likely depends on the level of transcriptional activity.

Surprisingly, using luciferase assays in MCF-7 cells, we found that in the extended BCL2 P1 promoter region containing both P1G4 and Pu39, P1G4 quadruplex appears to play a major role in repressing transcriptional activity. The G-quadruplex-interactive compound, TMPyP4, also induced a more pronounced inhibitory effect on the BCL2 P1 promoter activity through the P1G4 quadruplex. It has recently been shown that the complementary C-rich strand of Pu39 forms a i-motif, which is highly dynamic and exists in equilibrium with a flexible hairpin species.³⁰ Stabilization of the i-motif structure results in upregulation, whereas stabilization of the flexible hairpin results in downregulation of the BCL2 gene. Therefore, the effect of Pu39/Pu39 region on the BCL2 gene transcription may be more complicated and related to both quadruplex and i-motif on the complementary strands.

Parallel-stranded structures with three tetrads are found to be common in the promoter G-quadruplexes, while most parallel-stranded promoter G-quadruplexes contain three chain-reversal loops with 1-nt first and last loops and a variable-length middle loop.³¹ It is intriguing that the P1G4 G-quadruplex appears to be a dynamic equilibrium of two parallel structures, one broken-strand, both with a novel hairpin conformation adopted by the middle loop. DNA quadruplexes with duplex motifs have been shown to be quite tolerable.³² Unlike two interchangeable G-quadruplexes with distinct structures formed from Pu39, the two P1G4 conformations are very similar whose dynamic equilibrium may provide entropy and stability to the formation of the P1G4 G-quadruplex. This dynamic equilibrium of two closely related conformations and the unique hairpin loop are specific to the P1G4 sequence, distinguishing the P1G4 quadruplex from other parallel structures, and may be recognized by proteins or small molecules. The unique hairpin loop within the P1G4 quadruplex may provide a specific target for small molecule recognition.

MATERIALS AND METHODS

Oligonucleotides. Site-specific ¹⁵N-labeled and unlabeled DNA oligonucleotides were synthesized using β -cyanoethylphosphoramidite solid phase chemistry (Applied Biosystem Expedite 8909) as described previously.^{18,29,33} ¹⁵N-labeled guanine phosphoramidite was purchased from Cambridge Isotope Laboratories, Inc. (Andover, MA). 8% of ¹⁵N-labeled guanine phosphoramidite was mixed with 92% of unlabeled guanine phosphoramidite in site-specifically ¹⁵N-labeled

DNA synthesis. The synthesized oligonucleotides were eluted from the column with a 50%:50% mixture of 40% methylamine:ammonia, heated for 10 min at 65 °C, purified on reverse-phase Micropure II columns (BioSearch Technologies) and subjected to sequential dialysis through 10 mM NaOH, water, 150 mM NaCl, and water before lyophilization.

NMR Spectroscopy Study. NMR experiments were performed on a Bruker DRX-600 spectrometer. DNA oligonucleotides were prepared in either 50 mM or 25 mM K⁺-containing K-phosphate buffer (pH 7) solution, with a total final concentration of 0.1–2.5 mM DNA. The samples were prepared in 10/90% D₂O/H₂O solution. Each sample was annealed by heating at 95 °C for 5 min and cooling slowly to room temperature. 1D ¹H spectra were recorded at 25 °C with 512 scans. One-dimensional ¹⁵N-edited gradient HMQC experiments with site-specific ¹⁵N-labeling were performed to identify guanine imino H1 and aromatic H8 protons. The water signal was suppressed using a Watergate pulse sequence.

DMS Footprinting. Gel-purified Bcl-2 oligonucleotides (with 7T flanking ends) 5'-end labeled using [γ -³²P] ATP in the presence of T4 polynucleotide kinase were denatured at 90 °C for 5 min, then slowly cooled to room temperature in 10 mM Tris-HCl buffer (pH = 7.6) in the presence or absence of 140 mM KCl. The samples were then methylated by treatment with 0.5% (final concentration) DMS, 1 μ g calf thymus DNA for 7 min at room temperature. The reaction was stopped by the addition of β -mercaptoethanol and glycerol to final concentrations of 7.7% and 2.6%, respectively. In order to separate the single-stranded DNA, intramolecular G-quadruplex, and intermolecular G-quadruplexes, an 8% native PAGE gel was used. The DNA was recovered from the gel, ethanol-precipitated and subjected to cleavage with 10% piperidine for 16 min at 90 °C. A Speedvac was used to remove the piperidine and two successive water washes. The cleaved products (5500 cpm/5 μ L) were analyzed on a 16% sequencing (denaturing) PAGE gel. Because of the length of the 94-nt sequence, the same DMS footprinting sample series was loaded on the same gel at two different times to allow the best separation of 5' (Figure 3 left) and 3' (Figure 3 right) bands.

Circular Dichroism (CD) Spectroscopy. A Jasco-810 spectropolarimeter (Jasco Inc., Easton, MD) equipped with a thermodynamically controlled cell holder was used to obtain circular dichroism spectra. Ten μ M samples were prepared in 50 mM K⁺-containing K-phosphate buffer. Measurements were taken in a 1 mm optical path length quartz cell. The CD spectra were three averaged scans between 230 and 330 nm at 25 °C after application of a baseline correction to remove signal contributions from the buffer. CD melting experiments to obtain T_m values were performed at 264 nm with a heating rate of 2 °C/min and 1 s response time between 25 and 93 °C.

Preparation of Promoter Reporter Constructs. The P1G4 firefly luciferase construct was generated by inserting the human bcl-2 P1 promoter DNA sequence (−1390 to −1444 bp), containing the P1G4 sequence upstream of the firefly luciferase reporter gene in a promoter-less pGL4.13 vector in the same orientation as in the human bcl-2 gene (Figure 1B), using an oligonucleotide cassette cloning approach. The SV40 promoter normally present in pGL4.13 was deleted, as we found that the SV40 promoter contains a GC-rich region that can be affected by G-quadruplex-interactive small molecules. The control constructs (KO) were generated with a mutated G-quadruplex sequence that was not able to form G-quadruplex. To analyze the respective function of Pu39G4 and P1G4, we generated several other pGL4.13–SV40 luciferase constructs containing Pu39G4-P1G4 (Dual-WT), Pu39KO-P1G4 (Dual-Pu39KO), Pu39G4-P1G4KO (Dual-P1G4KO), and Pu39KO-P1G4KO (Dual-KOKO) sequences (Figure 1B). Most dual constructs have mutations to generate a BssHII site between Pu39 and P1G4 sequences to allow a cassette approach to construction. No significant difference in promoter activities was observed between wild-type and BssHII constructs.

For all promoter constructs, complementary custom DNA oligonucleotide pairs (Sigma, see Supplemental Table S2) at equimolar ratios were 5'-phosphorylated using T4 polynucleotide kinase (New England Biolabs, NEB) with T4 DNA ligase buffer

(NEB) for 2 h at 37 °C, then heated at 95 °C for 5 min and allowed to cool slowly, inactivating enzymes and annealing the strands to provide appropriate sticky ends. For double inserts, resulting equimolar dsDNA oligonucleotide pairs were ligated with T4 DNA ligase for 16 h at room temperature (RT). pGL4.13-SV40 plasmid was digested with SacI and XhoI, and the resulting ends were dephosphorylated with Antarctic phosphatase (NEB) for 2 h at 37 °C. The cut plasmid was then isolated via QiaQuick PCR purification kit. T4 DNA ligase (NEB) was used to ligate dsDNA oligonucleotide insert with cut plasmid at RT for 16 h. Successful clones were verified by sequencing.

Transfection and Luciferase Assay. MCF-7 cells (8×10^4) were cultured in 500 μ L RPMI including 10% FBS and 1% penicillin/streptomycin antibiotics overnight using a 24 well plate at 37 °C, 5% CO₂. Cell viability was assessed (>90%) by trypan blue prior to experiments. Two μ M of each plasmid construct was transfected into MCF-7 cells using Eugene HD (Promega). A Renilla luciferase plasmid, pRL-TK, was cotransfected with each construct for normalization. Transfection was performed in OptiMem serum-free medium, which was replaced by 10% FBS, 1% penicillin/streptomycin-supplemented RPMI after a 5 h incubation at 37 °C, 5% CO₂. After a further 24-h incubation, cells were lysed with Passive Lysis Buffer, and Firefly and Renilla luciferase activities were measured using the Dual-Luciferase Reporter assay kit (Promega).

For drug studies, MCF-7 cells were transfected with the constructs and treated with TMPyP4 and TMPyP2 5 h post-transfection at 5 μ M, lower than their IC₅₀ values.³⁴ At 24 h after small molecule compound treatment, cells were lysed and tested for Firefly and Renilla luciferase activity using the Dual-Luciferase Reporter assay kit (Promega). Luciferase activities expressed as relative luciferase units (RLUs) were normalized to total protein concentrations. Each transfection was run in triplicate or duplicate in each of three independent experiments.

Native Gel Electrophoresis. Electrophoresis experiments were performed with a 1.5 mm thick 10 \times 7 cm native gel containing 16% acrylamide (Acrylamide:Bis-acrylamide = 29:1) in TBE buffer, pH = 8 supplemented with 12.5 mM KCl. Each sample contains 0.4 nmol DNA. DNA bands were visualized using ethidium bromide staining.

■ ASSOCIATED CONTENT

● Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.5b08596.

The effects of TMPyP4 and TMPyP2 on luciferase activities, Oligonucleotides for luciferase assay, CD spectra of P1G4 and P1G4KO, Nondenaturing EMSA gels of P1G4 and P1G4T, 1D ¹H NMR of P1G4T, selected imino proton assignments of P1G4, CD spectrum of P1G4T_G8T, and NMR binding of NSC 59276 to P1G4T and the effect of NSC 59276 on the P1G4-driven luciferase activities. (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*yang@pharmacy.arizona.edu

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This research is supported by the National Institutes of Health (GM083117 and CA177585 to DY). We thank Clement Lin for proofreading the manuscript.

■ REFERENCES

- (1) Chao, D. T.; Korsmeyer, S. J. *Annu. Rev. Immunol.* **1998**, *16*, 395–419.
- (2) Letai, A.; Bassik, M. C.; Walensky, L. D.; Sorcinelli, M. D.; Weiler, S.; Korsmeyer, S. J. *Cancer Cell* **2002**, *2*, 183–192.

- (3) Tsujimoto, Y.; Croce, C. M. *Proc. Natl. Acad. Sci. U. S. A.* **1986**, *83*, 5214–5218.

- (4) Marschitz, I.; Tinhofer, I.; Hittmair, A.; Egle, A.; Kos, M.; Greil, R. *Am. J. Clin. Pathol.* **2000**, *113*, 219–229.

- (5) Pezzella, F.; Turley, H.; Kuzu, I.; Tungekar, M. F.; Dunnill, M. S.; Pierce, C. B.; Harris, A.; Gatter, K. C.; Mason, D. Y. *N. Engl. J. Med.* **1993**, *329*, 690–694.

- (6) McDonnell, T. J.; Troncoso, P.; Brisbay, S. M.; Logothetis, C.; Chung, L. W.; Hsieh, J. T.; Tu, S. M.; Campbell, M. L. *Cancer Res.* **1992**, *52*, 6940–6944.

- (7) Joensuu, H.; Pylkkanen, L.; Toikkanen, S. *Am. J. Pathol.* **1994**, *145*, 1191–1198.

- (8) Reed, J. C.; Kitada, S.; Takayama, S.; Miyashita, T. *Annals of Oncology* **1994**, *5* (Suppl 1), 61–65.

- (9) Renault, T. T.; Chipuk, J. E. *Ann. N. Y. Acad. Sci.* **2013**, *1285*, 59–79.

- (10) Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. *Nature* **2005**, *435*, 677–681.

- (11) Tse, C.; Shoemaker, A. R.; Adickes, J.; Anderson, M. G.; Chen, J.; Jin, S.; Johnson, E. F.; Marsh, K. C.; Mitten, M. J.; Nimmer, P.; Roberts, L.; Tahir, S. K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S. H.; Elmore, S. W. *Cancer Res.* **2008**, *68*, 3421–3428.

- (12) Souers, A. J.; Levenson, J. D.; Boghaert, E. R.; Ackler, S. L.; Catron, N. D.; Chen, J.; Dayton, B. D.; Ding, H.; Enschede, S. H.; Fairbrother, W. J.; Huang, D. C. S.; Hymowitz, S. G.; Jin, S.; Khaw, S. L.; Kovar, P. J.; Lam, L. T.; Lee, J.; Maecker, H. L.; Marsh, K. C.; Mason, K. D.; Mitten, M. J.; Nimmer, P. M.; Oleksijew, A.; Park, C. H.; Park, C.-M.; Phillips, D. C.; Roberts, A. W.; Sampath, D.; Seymour, J. F.; Smith, M. L.; Sullivan, G. M.; Tahir, S. K.; Tse, C.; Wendt, M. D.; Xiao, Y.; Xue, J. C.; Zhang, H.; Humerickhouse, R. A.; Rosenberg, S. H.; Elmore, S. W. *Nat. Med.* **2013**, *19*, 202–208.

- (13) Zinzalla, G.; Thurston, D. E. *Future Med. Chem.* **2009**, *1*, 65–93.

- (14) Choudhary, G. S.; Al-harbi, S.; Mazumder, S.; Hill, B. T.; Smith, M. R.; Bodo, J.; Hsi, E. D.; Almasan, A. *Cell Death Dis.* **2015**, *6*, e1593.

- (15) Juin, P.; Geneste, O.; Gautier, F.; Depil, S.; Campone, M. *Nat. Rev. Cancer* **2013**, *13*, 455–465.

- (16) Seto, M.; Jaeger, U.; Hockett, R. D.; Graninger, W.; Bennett, S.; Goldman, P.; Korsmeyer, S. J. *EMBO J.* **1988**, *7*, 123–131.

- (17) Young, R. L.; Korsmeyer, S. J. *Mol. Cell. Biol.* **1993**, *13*, 3686–3697.

- (18) Dai, J.; Dexheimer, T. S.; Chen, D.; Carver, M.; Ambrus, A.; Jones, R. A.; Yang, D. Z. *J. Am. Chem. Soc.* **2006**, *128*, 1096–1098.

- (19) Dexheimer, T. S.; Sun, D.; Hurley, L. H. *J. Am. Chem. Soc.* **2006**, *128*, 5404–5415.

- (20) Agrawal, P.; Lin, C.; Mathad, R. I.; Carver, M.; Yang, D. J. *Am. Chem. Soc.* **2014**, *136*, 1750–1753.

- (21) Wang, X. D.; Ou, T. M.; Lu, Y. J.; Li, Z.; Xu, Z.; Xi, C.; Tan, J. H.; Huang, S. L.; An, L. K.; Li, D.; Gu, L. Q.; Huang, Z. S. *J. Med. Chem.* **2010**, *53*, 4390–4398.

- (22) Onyshchenko, M. I.; Gaynutdinov, T. I.; Englund, E. A.; Appella, D. H.; Neumann, R. D.; Panyutin, I. G. *Nucleic Acids Res.* **2009**, *37*, 7570–7580.

- (23) Heckman, C.; Mochon, E.; Arcinas, M.; Boxer, L. M. *J. Biol. Chem.* **1997**, *272*, 19609–19614.

- (24) Beck, M. T.; Peirce, S. K.; Chen, W. Y. *Oncogene* **2002**, *21*, 5047–5055.

- (25) Chen, Y.; Agrawal, P.; Brown, R. V.; Hatzakis, E.; Hurley, L.; Yang, D. J. *Am. Chem. Soc.* **2012**, *134*, 13220–13223.

- (26) Hatzakis, E.; Okamoto, K.; Yang, D. *Biochemistry* **2010**, *49*, 9152–9160.

- (27) Zhang, Z.; Dai, J.; Veliath, E.; Jones, R. A.; Yang, D. Z. *Nucleic Acids Res.* **2010**, *38*, 1009–1021.

- (28) Szewczak, A. A.; Kellogg, G. W.; Moore, P. B. *FEBS Lett.* **1993**, *327*, 261–264.
- (29) Agrawal, P.; Hatzakis, E.; Guo, K.; Carver, M.; Yang, D. *Nucleic Acids Res.* **2013**, *41*, 10584–10592.
- (30) Kendrick, S.; Kang, H. J.; Alam, M. P.; Madathil, M. M.; Agrawal, P.; Gokhale, V.; Yang, D.; Hecht, S. M.; Hurley, L. H. *J. Am. Chem. Soc.* **2014**, *136*, 4161–4171.
- (31) Onel, B.; Lin, C.; Yang, D. *Sci. China: Chem.* **2014**, *57*, 1605–1614.
- (32) Lim, K. W.; Phan, A. T. *Angew. Chem., Int. Ed.* **2013**, *52*, 8566–8569.
- (33) Dai, J.; Chen, D.; Jones, R. A.; Hurley, L. H.; Yang, D. *Nucleic Acids Res.* **2006**, *34*, 5133–5144.
- (34) Izbicka, E.; Wheelhouse, R. T.; Raymond, E.; Davidson, K. K.; Lawrence, R. A.; Sun, D. Y.; Windle, B. E.; Hurley, L. H.; Von Hoff, D. D. *Cancer Res.* **1999**, *59*, 639–644.